{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T02:48:47Z","timestamp":1794019727580,"version":"4.8.0"},"reference-count":22,"publisher":"BMJ","issue":"4","license":[{"start":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T00:00:00Z","timestamp":1701216000000},"content-version":"unspecified","delay-in-days":28,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2023,11,2]]},"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>Another course of immune checkpoint inhibitors (ICIs) is often considered in patients with cancer progression and previous immune-related adverse events, including inflammatory arthritis (ICI-IA), but there are limited data regarding safety of ICI rechallenge in this setting. We aimed to assess the rate and clinical features associated with ICI-IA flare\/recurrence on ICI rechallenge.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We conducted a multicentre observational study including cancer patients with ICI-IA who started a second course of ICI more than 3 months after ICI discontinuation in four French university hospitals. Primary outcome was the frequency of ICI flare\/recurrence after ICI rechallenge.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Twenty-three patients were included. At the time of ICI rechallenge, 18 patients reported no symptoms of ICI-IA (78%) and 5 had grade 1 (22%), 11 patients (48%) were not receiving any ICI-IA treatment, 11 (48%) were still on prednisone, 2 (9%) were on conventional synthetic disease-modifying antirheumatic drugs and 1 (4%) on anti-IL-6. ICI-IA flare\/recurrence occurred in 12 patients (52%) with a median time of 1\u2009month after ICI rechallenge. ICI-IA phenotype, disease activity and ICI-IA treatment at the time of ICI rechallenge did not differ according to ICI-IA flare\/recurrence status.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>In this first observational study of ICI-IA patients rechallenged with ICI, about half of the patients experienced ICI-IA flare\/recurrence with a similar phenotype but occurring earlier than the initial ICI-IA, warranting close monitoring during the first month of retreatment. Risk of flare did not differ according to baseline immunosuppressive treatment at the time of rechallenge.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/rmdopen-2023-003795","type":"journal-article","created":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T12:55:55Z","timestamp":1701262555000},"page":"e003795","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":13,"title":["Immune checkpoint inhibitor rechallenge in patients who previously experienced immune-related inflammatory arthritis: a multicentre observational study"],"prefix":"10.1136","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-3755-4860","authenticated-orcid":false,"given":"Alexandra","family":"Ladouceur","sequence":"first","affiliation":[{"name":"Rheumatology, Centre Hospitalier Universitaire de Bordeaux Groupe hospitalier Pellegrin, Bordeaux, France"},{"name":"Rheumatology, McGill University Faculty of Medicine, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Barnetche","sequence":"additional","affiliation":[{"name":"Rheumatology, Centre Hospitalier Universitaire de Bordeaux Groupe hospitalier Pellegrin, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gael","family":"Mouterde","sequence":"additional","affiliation":[{"name":"Rheumatology, H\u00f4pital Lapeyronie, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Tison","sequence":"additional","affiliation":[{"name":"Rheumatology, CHRU de Brest, Brest, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0891-2269","authenticated-orcid":false,"given":"Samuel","family":"Bitoun","sequence":"additional","affiliation":[{"name":"Rheumatology, Universit\u00e9 Paris Saclay, H\u00f4pital Bicetre, Assistance Publique-H\u00f4pitaux de Paris, FHU CARE, Le Kremlin-Bicetre, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sorilla","family":"Prey","sequence":"additional","affiliation":[{"name":"Dermatology, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France"},{"name":"Pediatric Dermatology Unit, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Dutriaux","sequence":"additional","affiliation":[{"name":"Dermatology, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Gerard","sequence":"additional","affiliation":[{"name":"Dermatology, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Pham-Ledard","sequence":"additional","affiliation":[{"name":"Dermatology, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Beylot-Barry","sequence":"additional","affiliation":[{"name":"Dermatology, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maeva","family":"Zysman","sequence":"additional","affiliation":[{"name":"Pulmonology, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00e9mi","family":"Veillon","sequence":"additional","affiliation":[{"name":"Pulmonology, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Domblides","sequence":"additional","affiliation":[{"name":"Oncology, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amaury","family":"Daste","sequence":"additional","affiliation":[{"name":"Oncology, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marine","family":"Gross-Goupil","sequence":"additional","affiliation":[{"name":"Oncology, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baptiste","family":"Sionneau","sequence":"additional","affiliation":[{"name":"Oncology, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Lefort","sequence":"additional","affiliation":[{"name":"Oncology, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Larroquette","sequence":"additional","affiliation":[{"name":"Oncology, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3029-8739","authenticated-orcid":false,"given":"Christophe","family":"Richez","sequence":"additional","affiliation":[{"name":"Rheumatology, Centre Hospitalier Universitaire de Bordeaux Groupe hospitalier Pellegrin, Bordeaux, France"},{"name":"UMR CNRS 5164, Universit\u00e9 de Bordeaux Coll\u00e8ge Sciences de la Sant\u00e9, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8045-0180","authenticated-orcid":false,"given":"Marie-Elise","family":"Truchetet","sequence":"additional","affiliation":[{"name":"Rheumatology, Centre Hospitalier Universitaire de Bordeaux Groupe hospitalier Pellegrin, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Schaeverbeke","sequence":"additional","affiliation":[{"name":"Rheumatology, Centre Hospitalier Universitaire de Bordeaux Groupe hospitalier Pellegrin, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6729-6200","authenticated-orcid":false,"given":"Marie","family":"Kostine","sequence":"additional","affiliation":[{"name":"Rheumatology, Centre Hospitalier Universitaire de Bordeaux Groupe hospitalier Pellegrin, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,11,29]]},"reference":[{"key":"2025090313280201000_9.4.e003795.1","first-page":"6159","article-title":"Multinational association of supportive care in cancer (MASCC) 2020 clinical practice recommendations for the management of immune-mediated cardiovascular, rheumatic, and renal toxicities from checkpoint inhibitors","volume":"28","author":"Suarez-Almazor","year":"2020","journal-title":"Support Care Cancer"},{"key":"2025090313280201000_9.4.e003795.2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212257"},{"key":"2025090313280201000_9.4.e003795.3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01440"},{"key":"2025090313280201000_9.4.e003795.4","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217139"},{"key":"2025090313280201000_9.4.e003795.5","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx225"},{"key":"2025090313280201000_9.4.e003795.6","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the society for immunotherapy of cancer (SITC)","volume":"5","author":"Puzanov","year":"2017","journal-title":"J Immunotherapy Cancer"},{"key":"2025090313280201000_9.4.e003795.7","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2019.0013"},{"key":"2025090313280201000_9.4.e003795.8","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216109"},{"key":"2025090313280201000_9.4.e003795.9","unstructured":"Available: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_5x7.pdf"},{"key":"2025090313280201000_9.4.e003795.10","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1016\/j.jtho.2021.05.001","article-title":"Five year survival update from KEYNOTE-010: pembrolizumab versus docetaxel for previously treated, programmed death-ligand 1-positive advanced NSCLC","volume":"16","author":"Herbst","year":"2021","journal-title":"J Thorac Oncol"},{"key":"2025090313280201000_9.4.e003795.11","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab249"},{"key":"2025090313280201000_9.4.e003795.12","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1001\/jamaoncol.2020.3960","article-title":"Immune checkpoint inhibitor rechallenge after immune-related adverse events in patients with cancer","volume":"6","author":"Dolladille","year":"2020","journal-title":"JAMA Oncol"},{"key":"2025090313280201000_9.4.e003795.13","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001622","article-title":"Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade >\/=2 immune-related adverse events in patients with cancer","volume":"8","author":"Allouchery","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2025090313280201000_9.4.e003795.14","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006398","article-title":"Society for immunotherapy of cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology","volume":"11","author":"Naidoo","year":"2023","journal-title":"J Immunother Cancer"},{"key":"2025090313280201000_9.4.e003795.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"2025090313280201000_9.4.e003795.16","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1001\/jamaoncol.2019.1022","article-title":"Evaluation of readministration of immune checkpoint inhibitors after immune-related adverse events in patients with cancer","volume":"5","author":"Simonaggio","year":"2019","journal-title":"JAMA Oncol"},{"key":"2025090313280201000_9.4.e003795.17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.7609"},{"key":"2025090313280201000_9.4.e003795.18","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx642"},{"key":"2025090313280201000_9.4.e003795.19","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1002\/art.41068","article-title":"Safety and efficacy of immune checkpoint inhibitors in patients with cancer and preexisting autoimmune disease: a nationwide, multicenter cohort study","volume":"71","author":"Tison","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2025090313280201000_9.4.e003795.20","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.730320","article-title":"Safety and efficacy of the rechallenge of immune checkpoint inhibitors after immune-related adverse events in patients with cancer: a systemic review and meta-analysis","volume":"12","author":"Zhao","year":"2021","journal-title":"Front Immunol"},{"key":"2025090313280201000_9.4.e003795.21","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.1200\/JCO.19.00320","article-title":"Resumption of immune checkpoint inhibitor therapy after immune-mediated colitis","volume":"37","author":"Abu-Sbeih","year":"2019","journal-title":"J Clin Oncol"},{"key":"2025090313280201000_9.4.e003795.22","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s00262-016-1926-2","article-title":"Efficacy and toxicity of rechallenge with combination immune checkpoint blockade in metastatic melanoma: a case series","volume":"66","author":"Spain","year":"2017","journal-title":"Cancer Immunol Immunother"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2023-003795","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T20:28:09Z","timestamp":1756931289000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2023-003795"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":22,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,11,29]]},"published-print":{"date-parts":[[2023,11]]}},"alternative-id":["10.1136\/rmdopen-2023-003795"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2023-003795","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11]]}}}